Supernus Pharmaceuticals Total Liabilities 2011-2024 | SUPN

Supernus Pharmaceuticals total liabilities from 2011 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
Supernus Pharmaceuticals Annual Total Liabilities
(Millions of US $)
2023 $356
2022 $816
2021 $873
2020 $759
2019 $565
2018 $525
2017 $157
2016 $118
2015 $101
2014 $96
2013 $78
2012 $36
2011 $44
2010 $0
Supernus Pharmaceuticals Quarterly Total Liabilities
(Millions of US $)
2024-06-30 $358
2024-03-31 $375
2023-12-31 $356
2023-09-30 $373
2023-06-30 $373
2023-03-31 $880
2022-12-31 $816
2022-09-30 $840
2022-06-30 $854
2022-03-31 $811
2021-12-31 $873
2021-09-30 $745
2021-06-30 $787
2021-03-31 $753
2020-12-31 $759
2020-09-30 $801
2020-06-30 $825
2020-03-31 $576
2019-12-31 $565
2019-09-30 $550
2019-06-30 $541
2019-03-31 $545
2018-12-31 $525
2018-09-30 $501
2018-06-30 $462
2018-03-31 $473
2017-12-31 $157
2017-09-30 $134
2017-06-30 $117
2017-03-31 $116
2016-12-31 $118
2016-09-30 $112
2016-06-30 $108
2016-03-31 $97
2015-12-31 $101
2015-09-30 $88
2015-06-30 $82
2015-03-31 $76
2014-12-31 $96
2014-09-30 $90
2014-06-30 $61
2014-03-31 $69
2013-12-31 $78
2013-09-30 $111
2013-06-30 $96
2013-03-31 $38
2012-12-31 $36
2012-09-30 $42
2012-06-30 $42
2012-03-31 $43
2011-12-31 $44
2011-09-30 $0
2011-06-30 $0
2011-03-31 $0
2010-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.872B $0.608B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00